For those living with Huntington's disease, time has always been the cruelest variable — the disease arrives in midlife and takes everything, slowly and without mercy. This week, the FDA reversed its opposition to UniQure's gene therapy, clearing a regulatory path that had long been closed, and offering a patient community accustomed to disappointment a rare and fragile reason for hope. Lauren Holder, an advocate who carries the disease herself and watches its early signs emerge, gave voice to what that shift means not as a statistic, but as a life still being lived.
FDA Clears Path for Huntington's Gene Therapy as UniQure Advances Treatment
Huntington's disease patients living with neurodegenerative symptoms may benefit from new treatment pathway, offering hope for disease management.
A door opening for people living with a disease that steals everything
Mark
Why does the FDA's reversal matter so much for Huntington's patients? What was the barrier before?
Mimi
Gene therapy is still relatively new territory for regulators. The FDA had concerns about safety and efficacy. But UniQure's data apparently convinced them the potential benefit outweighs those risks. For patients, that means a therapy that could actually address the genetic cause—not just manage symptoms as they appear.
Mark
Lauren Holder is in the early stages of the disease. Does that change what this development means for her personally?
Mimi
It changes everything. She's still functioning, still able to advocate, still herself. But she knows what's coming. A gene therapy now could potentially slow or halt progression before the worst symptoms take hold. That's different from a treatment you'd start after you've already lost significant function.
Mark
The episode also covered RFK Jr.'s health agenda. Is there a connection between that and this FDA decision?
Mimi
Not directly—the FDA's reversal was based on the science and the data. But Kennedy's "Make America Healthy Again" platform includes a focus on rare diseases and precision medicine. The timing puts gene therapy in the spotlight as an example of what modern medicine can do.
Mark
What's the gap between FDA approval and actual patients getting the therapy?
Mimi
That's the real question. Approval is one hurdle. Then there's manufacturing, distribution, cost, insurance coverage. Gene therapies are expensive. The FDA clearing the path is necessary but not sufficient. It's the beginning of a much longer process.
Mark
Why did Holder's voice matter in this conversation?
Mimi
Because she's not abstract. She's not a statistic. She's someone who will potentially benefit from this therapy, and she's also someone who understands the Huntington's community deeply. She can speak to what patients actually need and what this reversal means in human terms.
Der Puls
- The FDA's reversal removes a significant regulatory barrier that had blocked UniQure's gene therapy from reaching U.S. patients with Huntington's disease.
- For a community that has endured repeated treatment failures, the shift carries unusual emotional weight — hope here is hard-won and easily lost.
- Unlike symptom-management approaches, this gene therapy targets the genetic origin of the disease itself, representing a fundamentally different medical strategy.
- Lauren Holder, in the early stages of Huntington's, brought the stakes into sharp relief on STAT's podcast — she is not observing this development from safety, but from inside it.
- Critical questions remain unanswered: whether UniQure's application will succeed, how quickly treatment could reach patients, and whether the cost of gene therapy will make it accessible to those who need it most.
For those living with Huntington's disease, time has always been the cruelest variable — the disease arrives in midlife and takes everything, slowly and without mercy. This week, the FDA reversed its opposition to UniQure's gene therapy, clearing a regulatory path that had long been closed, and offering a patient community accustomed to disappointment a rare and fragile reason for hope. Lauren Holder, an advocate who carries the disease herself and watches its early signs emerge, gave voice to what that shift means not as a statistic, but as a life still being lived.
Lauren Holder is a Huntington's disease advocate who speaks publicly about a condition she also carries. She has begun to see its early signs in herself — the slow erosion of motor control, cognition, and selfhood that defines the disease's progression. This week, she had something different to bring to that conversation: the FDA had reversed its opposition to a gene therapy that could change the course of the illness for people like her.
UniQure, a biotech company, had been developing a gene therapy for Huntington's — a rare, inherited neurodegenerative disorder that typically emerges in midlife and advances without pause. The agency had previously blocked the path forward. Its reversal now allows UniQure to file for U.S. approval, and for a patient community that has watched treatments fail and hopes dim, the change felt like a door finally opening.
Holder joined STAT's podcast to discuss what the decision means from the inside — not as a distant observer, but as someone in the early stages of the disease, aware of what lies ahead. The therapy she discussed is not about managing symptoms as they appear; it aims to address the genetic root of Huntington's itself, a fundamentally different kind of medicine.
The story sits at the intersection of individual hope and systemic uncertainty. A single regulatory reversal can mean everything to thousands of patients. But whether that hope becomes real depends on what follows — the success of UniQure's application, the speed of access, and whether the economics of gene therapy will allow it to reach those who need it most. Holder's voice on the podcast grounded all of it in something the data alone cannot carry: the experience of living with the disease now, watching the science move, and hoping the path just cleared leads somewhere.
Lauren Holder has lived long enough to see the disease she carries begin to show itself. She is a Huntington's advocate, which means she speaks publicly about a condition that will, over time, steal her motor control, her cognition, her sense of self. This week, she had something different to talk about on a podcast: the FDA had reversed course on a gene therapy that might change the trajectory for people like her.
The Food and Drug Administration's shift was significant. UniQure, a biotech company, had been developing a gene therapy for Huntington's disease—a rare, inherited neurodegenerative disorder that typically emerges in midlife and progresses relentlessly. The agency had previously opposed the approach. Now it was clearing the way for UniQure to file for approval in the United States. For a patient community that has watched treatments fail and hopes dim, the reversal felt like a door opening.
Holder joined STAT's podcast, "The Readout LOUD," to discuss what the FDA's decision meant for people living with Huntington's. She spoke from the vantage point of someone in the early stages of the disease—not yet devastated by it, but aware of what lies ahead. Her voice in the conversation carried the weight of that knowledge. The gene therapy represents a fundamentally different approach to treatment: rather than managing symptoms as they emerge, it aims to address the genetic root of the disease itself.
The episode also featured Isabella Cueto, STAT's chronic disease reporter, who has been tracking Robert F. Kennedy Jr.'s tenure as secretary of the Department of Health and Human Services. Kennedy entered the role on the promise of "Make America Healthy Again," a pledge that earned him the position. He arrived with an ambitious agenda and a two-year timeline to deliver measurable improvements in American health. Cueto's reporting has followed his actions and the movement's progress closely, offering a report card on how that effort has unfolded so far.
The convergence of these two stories—one about a specific breakthrough in gene therapy, the other about a broader effort to reshape American health policy—reflects the complexity of modern medicine. A single FDA reversal can mean hope for thousands of patients. But that hope depends on what happens next: whether UniQure's application succeeds, how quickly the therapy might reach patients, and whether the cost and logistics of gene therapy will make it accessible to those who need it most. Holder's presence on the podcast grounded the story in lived experience. She is not waiting for a cure from a distance. She is living with the disease now, watching the science advance, and hoping that the path the FDA has just cleared leads somewhere real.
Bemerkenswerte Zitate
Lauren Holder discussed the implications of the FDA's reversal for the Huntington's patient community— Lauren Holder, Huntington's disease advocate
Möchten Sie die ganze Geschichte?
Das Original lesen bei STAT ↗
Health & Medicine